Eliquis

This page shows the latest Eliquis news and features for those working in and with pharma, biotech and healthcare.

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

Overall, BMS reported an 8% increase in revenues to $5.7bn, with gains for Opdivo and Yervoy (up 18% to $382m) accompanied by a good performance from antiplatelet drug Eliquis (apixaban)

Latest news

Pfizer CEO reckons rebates will disappear, and that’s a positive

Eliquis (apixaban), which rocketed 47% to $889m.
Pfizer’s flat sales focus investor attention on M&A

Once again, cancer drug Ibrance (palbociclib), anticoagulant Eliquis (apixaban) and Xeljanz (tofacitinib) for arthritis and other immunological indications led the charge, backed up by a solid advance for paediatric vaccine Prevnar
Bad news for Portola as CHMP considers Factor Xa drugs

Eliquis (apixaban), Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa (edoxaban) - have thus far not been approved.
BMS’ Opdivo defies naysayers with healthy growth

Outside oncology, BMS’ top performer was novel oral anticoagulant Eliquis (apixaban), which grew 39% to $1.27bn, with Caforio claiming it is the most prescribed NOAC in the US, Japan and
Xarelto no better than aspirin in secondary stroke study

For years it led the market among NOAC drugs, keeping ahead of Pfizer and Bristol-Myers Squibb’s Eliquis (apixaban) and with Boehringer Ingelheim’s Pradaxa (dabigatran) and Daiichi Sankyo’s ... This year saw a reversal of fortune however, with

More from news
Approximately 14 fully matching, plus 69 partially matching documents found.

Latest Intelligence

The handover: Pfizer reshapes itself for a new era

Innovative health revenue increased 4% to $8.47bn, lifted by sales of blood thinner Eliquis and breast cancer drug Ibrance outside the US, among others.
The good, the bad and the ugly

This was largely thanks to Eliquis overtaking Bayer’s Xarelto as the leader in novel oral anticoagulants.
Modern anticoagulants threaten status quo

Apixaban. Bristol-Myers Squibb and Pfizer are developing apixaban (Eliquis), which is an oral, twice-daily, selective factor Xa inhibitor.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

PPD expands global product department with new therapeutic area heads

Puneet Mohan (left) comes to PPD from Bristol-Myers Squibb, where he most recently served as executive director of global clinical development and global clinical leader for Eliquis (apixaban).

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Manager: Negotiable

Account Manager – Creative Healthcare Advertising – Central Lond...: Salary TBC

Healthcare Communications Account Directors x 2: Salary TBC

Manager - Immunology, Therapeutic Area Communications & Publ...: Competitive Salary Offered

SAE – Healthcare PR – Award-Winning Consultancy: Salary TBC

Account Manager / Senior Account Manager: 35, 000-40, 000

Account Executive/ Senior Account Executive: competitive Salary Offfered

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Medical Writer: Salary TBC

Digital Communications Lead, Healthcare Brand and Medical Commun...: up to £50K

Account Manager- Healthcare Advertising: Negotiable

Account Director – Healthcare Marketing – Berks: Salary TBC

Principal Health Economist - North-West: Negotiable

Healthcare Advertising Senior Account Manager / AD / Senior AD: Salary TBC

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Account Manager / Account Director: Competative

Medical Writer: Bonus Scheme, PTO &Private Healthcare

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

Associate Medical Director: Excellent PTO, bonus and 401k package

Business Development Director – Health Education: excellent commission

Editorial Manager - MedComms: DOE

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Medical (Scientific) Director: £120, 000 benefits

Business Director: Competitive Salary Offered

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today: Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham: Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone: Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...